Focus
Rare Disease Investors: Angels and VC Firms
The RaiseHunt database lists 91 Rare Disease investors: 17 angel investors and 74 people at 30 firms. Most list Series A and Seed among their stages; the largest hubs are New York, Boston and Paris.
- 91
- Rare Disease investors
- 17
- Angel investors
- 74
- People at VC/PE firms
- 30
- Firms tagged
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
91 Rare Disease investors
Showing 1-20
| Investor | Location | Type | Markets | Contact | Actions |
|---|---|---|---|---|---|
David Jin angel investor | New York, United States | Angel | Healthcare | View profile | |
Mark Stoner angel investor and operator angel | San Francisco, United States | AngelOperator angel | AIFinTech | View profile | |
Thomas Zheng angel investor and operator angel | San Diego, United States | AngelOperator angel | AIHealthcare | View profile | |
Roger Jeffs angel investor and operator angel | Raleigh, United States | AngelOperator angel | Healthcare | View profile | |
Peter Hecht angel investor and operator angel | Cambridge, United States | AngelOperator angel | Healthcare | View profile | |
John Glasspool Venture Partner at Agent Capital | Boston, United States | Venture capital | AIHealthcare | View profile | |
Geeta Vemuri Founder at Agent Capital | Boston, United States | Venture capital | AIHealthcare | View profile | |
Callum Booker Founder at Agent Capital | Austin, United States | Syndicate / Angel groupVenture capital | AICommerce | View profile | |
Sunny Reddy Principal at Aisling Capital | New York, United States | Venture capital | Healthcare | View profile | |
Preston Noon Co-Founder at Agent Capital | Boston, United States | Venture capital | AIHealthcare | View profile | |
Danyin P. Chiesi Group at Chiesi Farmaceutici | Amsterdam, Netherlands | Corporate VC | AIHealthcare | View profile | |
Ross Lindsay Investor at Novo Nordisk | Cambridge, United Kingdom | Corporate VC | Healthcare | View profile | |
Nurdan Aydin Investment Partner at Novo Nordisk | Holbæk, Denmark | Corporate VC | Healthcare | View profile | |
Niklas Benedikt Grimm Researcher at Jazz Pharmaceuticals | Germany | Corporate VC | Healthcare | View profile | |
Jason Curry angel investor and operator angel | Pittsburgh, United States | AngelOperator angel | FinTechHealthcare | View profile | |
Andrew Kaplan Board Observer at Tanabe Pharma America | Boston, United States | Corporate VCPrivate equity | AICommerce | View profile | |
Fernando Castillo Lasheras angel investor and operator angel | Bilbao, Spain | AngelOperator angel | Healthcare | View profile | |
John McNamara Managing Director, Investments at Chan Zuckerberg Initiative | San Francisco, United States | Family Office | ClimateEducation | View profile | |
Daniel Burke Investor at Harrington Discovery Institute at University Hospitals | Cleveland, United States | Accelerator | Healthcare | View profile | |
David Lee Chief Investment Officer at Chan Zuckerberg Initiative | Palo Alto, United States | Family Office | ClimateEducation | View profile |
Frequently asked questions
How many Rare Disease investors are on RaiseHunt?
RaiseHunt currently lists 91 Rare Disease investors.
Are Rare Disease investors angels or funds?
Both. 17 are angel investors putting in their own money, and 74 are people making investment decisions at 30 firms.
Where are most Rare Disease investors based?
The largest concentrations are in New York, Boston and Paris.
What stage do Rare Disease investors invest at?
Most list Series A and Seed among the rounds they take part in.
How do I contact Rare Disease investors?
Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.
Is the list of Rare Disease investors free to browse?
Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.
Do Rare Disease investors only back Rare Disease companies?
No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.
What if no Rare Disease investor replies?
Usually the list was too short or too loosely matched, not that the company is unfundable. Widen it, tighten who you are writing to, and rewrite the first two lines of the message. Those lines decide whether anything below them gets read.
What is the difference between an angel investor and a VC fund?
An angel invests their own money and can decide alone, which usually makes the process shorter. A fund invests money it raised from other people, so it answers to those backers and normally runs a longer diligence process before it commits. Founders often raise from angels first and bring in a fund once there is more to show.
How many Rare Disease investors should I contact?
Far more than feels comfortable. Response rates on cold outreach are low even when the fit is good, so a list of a handful of perfect names tends to stall. Build a long list, sort it by how well each one matches what you are building, and work down it in batches rather than sending everything at once.
What should I have ready before reaching out?
A short deck, a one-paragraph description of what you do and who it is for, and a clear number for how much you are raising. Investors read the first two lines before they decide whether to open the deck, so those lines matter more than the rest of the document.
Does a warm introduction still matter?
It helps, mostly because it moves your email out of a crowded inbox. It is not a requirement. A cold message that shows you understand what someone has already backed, and why your company fits that pattern, gets read more often than a vague introduction from a distant contact.
Data: RaiseHunt investor dataset · Snapshot 27 August 2026 · How this data is built · Report a correction or request removal
